✦ LIBER ✦

547 Improvements in survival and clinical benefit with the use of gemcitabine (GEM) as first-line therapy for advanced pancreatic cancer: A randomized trial

✍ Scribed by M. Moore

Book ID: 116167300
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 318 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(95)95801-c

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized and open-label trial evalua

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

✍ Stephen R. D. Johnston, Henry Gómez, Salomon M. Stemmer, Maria Richie, Michael D 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 436 KB

Gemcitabine and oxaliplatin followed by

Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study

✍ C.B. Steer; K. Chrystal; K.A. Cheong; E. Galani; G.M. Marx; A.H. Strickland; D. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 146 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

127Immediate hormonal therapy improves l

127Immediate hormonal therapy improves locoregional control and survival in patients with locally advanced prostate cancer. Results of a randomized phase III clinical trial of the eortc radiotherapy and genito-urinary tract cancer cooperative groups

✍ Bolla, M.; Gonzelez, D.; Warde, P.; Dubois, J.B.; Mirimanoff, R.; Storme, G.; Be 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 105 KB

A phase II open-label randomized study t

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

✍ György Bodoky, Constanta Timcheva, David Robert Spigel, Phillip Joseph La Stella 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 640 KB